NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks delivered a positive return of 2.2%, while the Danish biotech stocks rose 1.9%. Zealand Pharma, IO Biotech, Y-mAbs Therapeutics, and Evaxion Biotech presented interesting study data with Zealand Pharma presenting the most notable one. Their obesity drug showed an average weight loss of 8.5% vs. placebo in a 13-week trial. Curasight published their prospectus for their rights issue.
9 of the 22 Danish biotech companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 306% return and Audientes was the best Nordic healthcare investment last week. Six Danish healthcare stocks with +100% YTD return.
Danish company news
Acarix informs of exercise price for the warrants of series TO 3 (Link)
Board member purchases shares in Acarix (Link)
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults (Link)
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 (Link)
No news the past week
No news the past week
No news the past week
Curasight A/S publishes prospectus due to upcoming rights issue (Link)
Commencement of subscription period in Curasight’s preferential rights issue (Link)
No news the past week
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 (Link)
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 (Link)
No news the past week
No news the past week
No news the past week
Major shareholder announcement (Link)
No news the past week
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (Link)
No news the past week
No news the past week
No news the past week
SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence (Link)
No news the past week
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide (Link)
BTIG increased its price target from DKK 1,050 to DKK 1,100.
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research (Link)
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a return of 1.9%. Cessatech and Pila Pharma rose 45% and 28% respectively without any company-specific news. Zealand Pharma rose 11% following the announcement of positive topline results in a phase Ib study with Dapiglutide that showed an average weight loss of 8.5% after 13 weeks compared to placebo. Furthermore, Ascendis Pharma received Orphan Drug Exclusivity for YORVIPATH, IO Biotech announced positive phase II results of IO102-IO103 against advanced head and neck cancer, Evaxion reported a 69% overall response rate in a phase II study with EVX-01, a board member of Acarix bought shares, and Y-mAbs Therapeutics presented research on their Naxitamab and SADA PRIT Technology Platform. Finally, Curasight published its prospectus for its rights issue.
Gubra continue to be the best-performing stock year-to-date with a return of 306%. Y-mAbs Therapeutics, Pila Pharma, Cessatech, Zealand Pharma, and CS Medica have also generated returns of over 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 2.2% to 68,22. The index has had a strong performance since the beginning of April and it has now not only surpassed the KPNGX index but it has also joined the larger indexes in terms of performance. In the past 12 months, the KPHC index has still underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by quite a lot.
Price charts for the KPHC, KPNGX, C25, and S30 index for the past twelve months
45-70% in weekly return for the Nordic healthcare stocks
Audientes (70%) is a Danish technology company specialized in the development of hearing aids. Audientes’ hearing aid solution, Ven™ by Audientes, is available in the Indian market, online and through retailers. Audientes’ vision is to develop products that can be used by people suffering from hearing loss who currently do not have access to a solution for their hearing loss.
Klaria Pharma Holding AB (51%) is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company’s drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient’s oral mucosa, which enables the distribution of pharmaceuticals in the body.
Cessatech A/S (45%) specializes in the research and development of analgesic nasal sprays, which are further used to treat acute pain conditions in children. In addition to the main business, associated complementary services and related products are also offered. The business operates globally with the largest presence in the Nordic market.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
